• Molecular imaging (PET or MRI) has various impacts in different clinical scenarios.
Introduction
Molecular imaging is a means of in vivo visualization of the key molecularly based events, which represents the cancer phenotype and has potential as imaging biomarkers [1] applied in cancer management [2] . Magnetic resonance imaging (MRI) has advanced toward scale beyond the anatomical structures in many aspects. Diffusion-weighted imaging (DWI) measures Brownian motion of molecules and highlights the increased cellularity of cancer tissue, which can be quantitatively evaluated on the apparent diffusion coefficient (ADC) map [3] . Dynamic contrast enhancement (DCE)-MRI makes use of intravenous gadolinium-based contrast agent that is blocked by the tight-junction of the normal blood vessel but leaks out through the neovascularization in the tumor, which provide profuse modeling information such as blood flow, extraction fraction, blood volume, volume of extravascular extracellular space (ESS), capillary permeability surface area product and transfer from blood to EES (Ktrans) [4] . MR spectroscopy (MRS) is a technique that can semi-quantitatively acquire chemical composition in a selected region of interest [5] . Nowadays most clinical MR scanners have routine sequences for proton ( 1 H)-MRS measurements, providing a range of metabolic and functional information integrated with complementary MRI localization. Positron emission tomography (PET), on the other hand, can provide functional or metabolic information with specifically labeled radiotracers suitable for different disease scenarios [6] . Integrated PET and computed tomography (PET/CT) scan using 18 F-fluorodeoxyglucose (FDG) is now widely used clinically, and many potential radiotracers other than FDG are under development (Table 1 ). In addition to radiotracers development, imaging parameter breakthrough has translated the semi-quantitative information of tumor to our daily practice, e.g. standardized uptake value maximum (SUVmax), total lesion glycolysis (TLG), metabolic tumor volume (MTV). Texture feature technology has been developed in PET recently and showed improvement in describing intratumoral heterogeneity and tumor landscape in certain cancers [7] . Through the strength of low radiation dose and high soft tissue contrast, the introduction of hybrid PET/MRI may possibly bring molecular image in clinical application to a new era [8] .
The purpose of this review is to summarize literature pertaining to clinical roles of MRI and PET for gynecologic malignancies (Table 2) and emerging techniques of these two major molecular imaging tools.
Diagnosis of malignancy
Molecular imaging may predict the degree of malignancy in ovary tumors or uterine sarcoma sparing endometrium. This function in Table 1 PET radiotracers for evaluation of biologic processes in oncology.
PET radiotracer
Biologic process/molecular target of interest 18 cervical cancer, endometrial cancer or vulvar cancer is less prominent because tissue diagnosis is often made before surgical intervention. Risum et al. showed that FDG-PET/CT is superior to CT or conventional MRI, in distinguishing malignant or borderline tumor from benign ovarian tumors, yielding a sensitivity of 92-100% and a specificity of 85-92.5% in identifying primary ovarian cancer in patients with a pelvic mass and risk of malignancy index (RMI) N 150 [9] . In a recent preliminary report the choline peak on MR spectra was detected in malignant ovarian tumors and was absent in apparently healthy pelvic tissues, which opens new research window for early diagnosis of ovarian cancer [10] . In preoperative diagnosis of uterine leiomyosarcoma, Tanaka [13] . To date no adequate evidence has been provided by a large scale or prospective study partly because of rareness of uterine sarcoma. In cervical cancer, radiotracers other than FDG such as 64 Cu-labeled diacetylbis(N4-methylthiosemicarbazone) ( 64 Cu-ATSM) were used to demonstrate hypoxia and 11 C-choline for proliferative
activity, yet have not gained popularity [14] .
Clinical staging of disease extent
Precise clinical staging is crucial for selection of primary therapy for cervical cancer. Generally, International Federation of Gynecology and Obstetrics [FIGO] stages IA1-IIA1 diseases can be treated with either primary surgery or radiotherapy (RT), while stages IB2 to IV (except IIA1) diseases can be treated with definitive radiation with concurrent platinum-based chemotherapy [14] . MRI was found useful to confirm the absence of residual tumor in the cervix after a cone biopsy with negative margins in selection of patients for fertility-sparing radical trachelectomy [15] . Results of the intergroup study American College of Radiology Imaging Network (ACRIN) 6651/Gynecologic Oncology Group (GOG) 183 showed that, in patients with early-stage cervical cancer scheduled for curative radical hysterectomy, MRI is superior to CT by receiver operating curve (ROC) analysis (area under the curve [AUC] 0.80 vs. 0.66, respectively; p b 0.01), for evaluating uterine body involvement and measuring tumor size [16] , and has a sensitivity of 53% and a specificity of 74% in detection of parametrial invasion (≥IIB) [17] . A European multicenter trial to evaluate tumor delineation by MRI in early-stage cervical cancer showed that, the agreement between MRI and histology was good for classifying tumors as b2 cm, or N 4 cm, and detecting deep stromal invasion (kappa values of 0.77, 0.76, 0.77, respectively), but only moderately accurate in assessing parametrial invasion (kappa values of 0.52, 0.45, respectively) [18] .
Data from the ACRIN 6651/GOG 183 study showed MRI has only a sensitivity of 37% but a specificity of 94% in detecting pelvic lymph node (LN) metastases [19] . Lin et al. has demonstrated a combination of size and relative ADC values on DWI being useful in detecting pelvic LN (PLN) metastasis in patients' population mixed with cervical and endometrial cancer, trying to provide a better sensitivity (25% vs. 83%) and maintain a similar specificity (98% vs. 99%), as compared with conventional MRI [20] . Chou et al. [21] showed that FDG-PET detected only one of the 10 MRI-negative pelvic metastatic LNs in patients with primary, non-bulky, stages IA2 to IIA cervical cancer. The PET falsenegative PLN containing micro-metastasis measured a short axis diameter of only 0.5-6 mm [21] . Kitajima showing that DWI has a higher sensitivity (83.3% vs. 38.9%) but a lower specificity (51.2% vs. 96.3%) than FDG-PET/CT [22] . Kim et al. evaluated the additional diagnostic value of FDG-PET and MRI fusion in the detection of metastatic LNs in cervical cancer patients, with the sensitivity and specificity of FDG-PET/CT and fused FDG-PET/MR being 44.1%, 93.9% and 54.2%, 92.7% respectively [23] .
Detection of paraaortic LN (PALN) metastasis is an important issue because extended-field RT is indicated based on PALN positivity, although it remains controversial whether extraperitoneal paraaortic lymphadenectomy should be performed [24] . In patients having negative findings of PALN on CT or MRI, the sensitivity and specificity of FDG-PET/CT were 33-36% and 94-96%, respectively, using laparoscopic paraaortic lymphadenectomy histology as a gold standard [25, 26] . In patients with stage IB/IIB cervical adenocarcinoma or adenosquamous carcinoma, the diagnostic efficacy in identifying metastatic PALN was significantly higher in FDG-PET than in MRI, with a sensitivity of 66.7% and a specificity of 100%, based on surgical histopathology [27] . Tsai et al. demonstrated that pretreatment FDG-PET improves the detection of extrapelvic metastasis on MRI, mainly PALN, and helps to select patients for extended-field RT, albeit not translating into survival benefit, even with a reduced rate in PALN relapse [28] .
For patients who present with distant metastatic disease (i.e., stage IVB), primary treatment is often cisplatin-based chemotherapy. In these situations, individualized RT may be considered for control of pelvic disease and other symptoms. For newly diagnosed cervical cancer FIGO stage ≥ IB, FDG-PET/CT has a sensitivity of 100% and a specificity of 94% in detecting distant metastases [29] . Liu et al. demonstrated the superiority of FDG-PET over CT and MRI for detecting hematogenous bone metastasis in FIGO stage III/IV or positive LN metastasis cervical cancer patients upon primary staging [30] . However, FDG-PET/CT should be interpreted cautiously for isolated mediastinal involvement in newly diagnosed cervical cancer patients, because 75% of the mediastinal LNs with increased FDG uptake were eventually confirmed histopathologically to be granulomatous changes only and free of tumor [31] .
For endometrial cancer, Antonsen et al. reported a Danish multicenter prospective comparative study showing the prediction of myometrial invasion, the sensitivity and specificity being 93% and 49% for FDG-PET/CT, and 87% and 57% for conventional MRI [32] . Lin et al. demonstrated fused T2-weighted and high-b-value DWI at 3T can provide accurate information for preoperative evaluation of myometrial invasion, with a sensitivity of 86% and a specificity of 100% [33] . Regarding the detection of cervical invasion, the sensitivity of both FDG-PET/CT and MRI was suboptimal (43% and 33%, respectively) [32] .
For preoperative diagnosis of LN metastases in patients with endometrial carcinoma, the sensitivity and specificity of FDG-PET/CT were 67-74% and 93-94% respectively, superior to those of MRI, 59% and 93%, proven by surgical staging [32, 34] . Suzuki et al. reported that FDG-PET had a sensitivity superior to CT/MRI, in detection of extrauterine lesions excluding retroperitoneal LNs (83.3% vs. 66.7%), although there was no difference in the specificity among the modalities (100%) [35] . FDG-PET also had a higher specificity (100%) compared with CT/ MRI (85.7%), but still could not detect LN metastatic lesions smaller than 0.6 cm in short-axis diameter [35] . Ho et al. [36] showed that FDG-PET is beneficial in excluding falsely inoperable carcinosarcoma for curative therapy and in making a decision on palliation for better quality of life instead of aggressive treatment.
Regarding ovarian cancer, Hynninen et al. showed a substantial number of patients with advanced ovarian cancer stages IIC-IV showing supra-diaphragmatic nodal metastasis in pre-treatment FDG-PET/CT, suggesting that the route of ovarian cancer cells from the peritoneal cavity to the lymphatic system permeates the diaphragm mainly to the cardiophrenic node and continues to the parasternal LNs [37] . A meta-analysis demonstrated that, FDG-PET or FDG-PET/CT (sensitivity, 73.2%; specificity, 96.7%) is more accurate than CT (sensitivity, 42.6%; specificity, 95.0%) or MRI (sensitivity, 54.7%; specificity, 88.3%) in the detection of LN metastasis in patients with ovarian cancer [38] , while Michielsen et al. found that whole body MRI with DWI has a higher accuracy (91%) as compared with CT (75%) or FDG-PET/CT (71%) for peritoneal staging [39] . This is in line with our experience showing an additional DWI that could improve the performance of MRI, but reader experience still plays crucial roles in imaging interpretation.
Kataoka et al. reported that MRI has an accuracy of 85% in staging of primary vulvar cancers, and 87% in the prediction of groin nodal metastasis [40] . Cohn et al. showed that FDG-PET is relatively insensitive, with a sensitivity of 67% and a specificity of 95%, in predicting groin nodal metastasis, whereas FDG-PET is more accurate for detecting extranodal metastases than the disease confined within the groin nodes (p = 0.048) [41] .
Prognostic implications
In addition to anatomical details, molecular imaging also provides quantitative information as prognostic indicators. Kidd and Grigsby showed that in FIGO stages IB1 to IVA cervical cancer treated with chemoradiation, intratumoral FDG metabolic heterogeneity on the pretreatment FDG-PET predicted the risks of LN involvement at disease diagnosis, response to therapy and pelvic recurrence [42] . Crivellaro et al. showed that in patients with cervical cancer FIGO stages IB1 and IIA with tumor less than 4 cm, MTV and TLG of cervical lesions on FDG-PET/CT predict nodal metastases but does not predict recurrence [43] . Yen et al. showed that a SUVmax ≥ 3.3 for PALN and FIGO stage ≥ III were adverse factors for patients with primary squamous cervical carcinoma with PLN or PALN metastasis detected by CT/MRI [44] . Results from Ho et al. justified the use of FDG-PET (accurate extent of relapse and SUV) as a prognostic tool in cervical cancer patients with supraclavicular LN recurrence, showing that SUV of b 4.3 or N 8 were significant adverse prognostic factors by multivariate analysis [45] .
Antonsen et al. found that preoperative SUVmax of endometrial tumor is significantly higher in patients with high FIGO stages, deep myometrial invasion, cervical invasion, LN metastasis and high-risk tumors. However, the sensitivity and specificity of the SUVmax in staging endometrial cancer is not high enough to reliably replace surgical staging [46] . The preoperative SUVmax is also superior to ADCmin of the primary tumor as a predictor of disease recurrence and survival in patients with endometrial cancer [47] . Liu et al. reported that MTV by FDG-PET/CT is prognostic for stage IVB endometrial carcinoma [48] , with 4 patients with total body MTV above 450 mL (or total body TLG above 2700 g) having a median survival of 2 months, while the remaining patients having a median survival of 47 months.
Response evaluation, surveillance, and the management of recurrence
Imaging is indicated in patients with symptoms or findings that are suspicious for recurrence but not routinely recommended for surveillance [49] . According to the NCCN Guidelines, in patients at high risk for locoregional failure, a combined PET/CT scan (e.g., 3-6 months after treatment) or other radiologic imaging may be useful for detecting asymptomatic disease that is potentially curable [49] . deSouza et al. assessed tumor response to neoadjuvant chemotherapy prior to radical hysterectomy in FIGO stages IB-IIB previously untreated cervical tumors N10 cm 3 , and found a significant reduction in tumor volume on MRI and \CH 2 triglyceride levels on MRS after neoadjuvant chemotherapy [50] . Furthermore, Harry et al. showed that ADC values was reproducible and showed a significant correlation with eventual clinical response, hence has potential to provide a surrogate biomarker of treatment response in advanced cervical cancers [51] . In patients with cervical cancer who experienced complete responses to primary treatment or salvage therapy, there is no evidence of recurrent disease as detected by conventional CT or MRI, but had serum squamous cell carcinoma antigen (SCC-Ag) level elevation on two consecutive occasions. Chang et al. demonstrated that FDG-PET expedited the detection (94%) of recurrence [52] . Chung et al. reported that the overall sensitivity and specificity of post-treatment FDG-PET/ CT were 94.7% and 87.8% [53] . Yen et al. defined the priority of using FDG-PET in cervical cancer patients after a definitive treatment with documented failure or unexplained elevated tumor marker in serum. Primary radiation treatment, SCC-Ag ≥ 4 ng/mL, and the presence of symptoms at recurrence were significant factors of poor survival. FDG-PET may offer maximal benefits by selecting appropriate recurrent cervical cancer patients for salvage therapy with precise restaging information [54] . In patients with cervical carcinoma who experienced confirmed treatment failure but who were feasible candidates for curative salvage therapy, FDG-PET was significantly superior to CT/MRI (sensitivity: 92% vs. 60%) in identifying metastatic lesions, and led to treatment plan modifications in 55% of the participants [55] . The benefits of FDG-PET exceed those of CT-MRI mainly because of the ability of FDG-PET to identify extra-pelvic metastases and its higher sensitivity and specificity [56] . Overall FDG-PET has a positive impact on 46% patients in cervical cancer patients with histologically documented rerecurrence after curative salvage therapy or unexplained tumor marker elevation [57] .
Park et al. evaluated the clinical impact of FDG-PET or FDG-PET/ CT in the post-therapy surveillance of endometrial carcinoma. In patients with suspected disease recurrence, the sensitivity and specificity of FDG-PET and/or FDG-PET/CT in detecting recurrence in these patients were 100% and 83.3%, respectively. In asymptomatic patients for routine post-therapy surveillance, the sensitivity and specificity of FDG-PET or FDG-PET/CT were both 100%. FDG-PET and/or FDG-PET/CT were highly effective in discriminating true recurrence in patients with suspected recurrence, highly sensitive in detecting recurrence in asymptomatic patients, and had impacts on clinical decisions in a considerable portion of patients [58] . Chao et al. reported that, in primary advanced (stage III/IV), or suspicious/documented recurrent endometrial cancer or surveillance after salvage therapy, FDG-PET plus MRI or CT was significantly superior to MRI or CT alone in overall lesion detection, detection of pelvic nodal/soft tissue metastases and detection of extrapelvic metastases (AUC 0.949 vs. 0.872; p = 0.004). Positive clinical impact was more often seen among those for suspicious/documented recurrence or post-salvage surveillance (70%) than primary staging (22.2%) [59] . Sironi et al. examined the value of integrated FDG-PET/CT in the detection of recurrence in postsurgical surveillance of patients with cervical or endometrial cancer with suspicion of recurrence based on the results of routine follow-up procedures, demonstrating a patient-based sensitivity and specificity of FDG-PET/CT for the detection of tumor recurrence were 92.9% and 100.0% [60] . Ho et al. [36] reported that FDG-PET has a limited value in post-therapy surveillance or restaging after failure for uterine carcinosarcoma. In another series comprising patients with uterine leiomyosarcoma, carcinosarcoma or endometrial stromal sarcoma after treatment, FDG-PET/CT had a sensitivity of 85.7% and a specificity of 100%, for detecting recurrence, which was higher than that of conventional CT or MRI, albeit not statistically significant [61] . FDG-PET/CT had an extremely high sensitivity of 100% and specificity of 100% for the detection of recurrent uterine leiomyosarcoma in a small retrospective study [62] . Murakami et al. advocated that application of FDG-PET imaging for the early detection of recurrent sites was useful in the decision of treatment strategy for patients with recurrent uterine sarcoma [63] .
In detecting recurrent ovarian cancer, FDG-PET/CT had a sensitivity of 85-97% and a specificity of 90-100% and was higher than those of ultrasonography and CT [64] , although negative predictive value is low (42.9%) because of the high rate of false-negative findings for micro or cystic lesions [65] . FDG-PET/CT modified the diagnostic or treatment plan, by leading to the use of previously unplanned therapeutic procedures in 57.9% of patients and the avoidance of previously planned diagnostic procedures in 42.1% of patients [66] .
Emerging molecular imaging techniques

PET/MR
The recently introduced hybrid PET/MR might improve the diagnostic performance of PET/CT, based on the major strengths of MRI over CT, including superior soft tissue contrast, multiplanar image acquisition and functional imaging capability through specialized techniques. Moreover, the absence of radiation using MR might be particularly beneficial in pediatric, young adult, or pregnant patients [8] . Initial results (n = 19) in cervical cancer from hybrid PET/MR including Grueneisen et al. revealed a significant inverse correlation between SUVmax and ADCmin of primary tumors (R = −0.342, p b 0.05) and associated primary LN metastases (R = − 0.692, p b 0.001), measured in a hybrid PET/MR system, whereas recurrent cervical cancer lesions did not show a significant correlation [67] . Hybrid PET/MR has also been applied for radiation treatment planning in cervical cancer patients but the results are controversial. Zhang et al. reported that tumor volume discrepancies were observed between MR-GTV (manually T2-weighted) and PET-GTV (auto-contoured by 40% SUV threshold) [68] , but a strong volume concordance between FDG-PET, and T2-weighted and DWI was reported by Sun et al. [69] . Cost-effectiveness analysis should be used as an end point in researches using new PET and MRI technologies.
PET texture analysis
Texture analysis is an image process technique analyzing a set of quantified metrics to represent the spatial arrangement of intensities in a volume of interest on PET. Coarseness, contrast and heterogeneity are frequently encountered metrics [70] . Although there is currently no evidence of connection between image texture and tumor heterogeneity at the cellular level, many researchers have tried texture analysis techniques on functional PET or structural CT and MR images to find potential parameters for prognosis and treatment response, as alternatives to traditional parameters such as tumor volume and SUV. Yang et al. had conducted a pilot study with 20 cervical cancer patients treated with combined chemoradiation and suggested some texture parameters may be better than SUV in predicting treatment outcome during the early phase of treatment [71] . However, by finding a few potential ones from a pool of numerous parameters with mathematical variation in a limited set of patients, further prospective, large-scale studies have to be performed with the exact same parameters to validate their true utility. Texture analysis on functional and structural medical images is a complicated field with potentiality and with many questions to be clarified [72] .
Dynamic nuclear polarization (DNP)
Dynamic nuclear polarization (DNP) is a novel imaging technique which uses specialized instrumentation to provide signal enhancements of over 10,000-folds of magnitude for stable isotope carbon-13 ( 13 C) enriched compounds [73] . Hyperpolarized [1-13 C]pyruvate has been used to study the real-time flux of pyruvate to lactate noninvasively following anticancer therapies in xenograft models. In addition to pyruvate, hyperpolarized H 13 CO 3 − has been demonstrated to measure extracellular pH in lymphoma xenograft and [1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]fumarate showed the potential as an indicator of necrotic cell death [73] . The first clinical trial of DNP-MRS has recently demonstrated the use of hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate to examine prostate cancer metabolism in human [74] , and paves the way to rapid translation of this exciting technology to clinical research and perhaps clinical practice.
Chemical exchange saturation transfer (CEST) imaging
Chemical exchange saturation transfer (CEST) imaging is an emerging MRI approach in which exogenous or endogenous compounds containing either exchangeable protons or exchangeable molecules are selectively saturated and after transfer of this saturation, detected indirectly through the water signal with enhanced sensitivity [75] . By measuring the uptake of unlabeled glucose to be measured through the chemical exchange of protons between hydroxyl groups and water, Walker-Samuel et al. demonstrated that CEST was sensitive to tumor glucose accumulation in colorectal tumor models and could distinguish tumor types and potentially assessing response to therapy in the clinic [76] . CEST using amide proton transfer imaging added to a standard MR at 3T has been reported to have significantly increased signal intensity in brain tumor of 12 patients [77] , yet there is no boundary to apply this technique in the field of gynecologic oncology.
Conclusions
In summary, molecular imaging (mainly PET and MRI) has played important roles in gynecologic oncology, for tumor detection, primary staging, treatment planning, prediction of prognosis, as well as response evaluation, surveillance, and the management of recurrence. Emerging imaging technologies will continuously improve our practice. Such development will aid decision-making in personalized medicine and precisely guide radiation treatment plan or real-time surgical interventions, which will directly impact on patient survival. No single imaging tool will universally apply in different tumor types. Prospective studies with defined endpoints are necessary to evaluate the roles of these emerging tools in management of gynecologic malignancies.
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